Drug Trial Radar · NCT01040780
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
Last checked: Nov 19, 2026Latest source record: Feb 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
399
Actual
Start
Feb 2009
Primary completion
Mar 2010
Study completion Dec 2011
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.
Conditions
- Non-small Cell Lung Cancer
Interventions
IcotinibDrug
125 mg three times daily (375 mg per day) by mouth
GefitinibDrug
250 mg every 24 hours by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 2-7 months
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital
Beijing, Beijing Municipality, China
Cancer Hospital, Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Bejing Cancer Hospital
Beijing, Beijing Municipality, China
307 Hospital of PLA
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital
Beijing, Beijing Municipality, China
Third Affiliated Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Guanghzou General Hospital of PLA
Guangzhou, Guangdong, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Sun yat-sen Univerisity Cancer Center
Guanzhou, Guangdong, China
the Second Xiangya Hospital,Central South University
Changsha, Hunan, China
Hunan Cancer Hospital
Changsha, Hunan, China
81 Hospital of PLA
Nanjing, Jiangsu, China
Nanjing General Hospital of Nanjing Command,PLA
Nanjing, Jiangsu, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
Ruijin Hospital,Shanghai Jiao-Tong University
Shanghai, Shanghai Municipality, China
Zhongshan Hospital,Fudan University
Shanghai, Shanghai Municipality, China
Changhai Hospital, Second Military Medical University
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Tangdu Hospital, Fourth Military Medical University
Xi’an, Shanxi, China
Xijing Hospital, Fourth Military Medical University
Xi’an, Shanxi, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.